Syndex
Santa Monica, US · Founded 2022 · 3 known investors
Find your way into Syndex
506 people in our graph share verified history with the Syndex team — schools, employers, funds. One of them is your warm intro.
Kevin Johnsonunlockedknows Geoff Smith · together at University of Cambridge (overlapped)
×3knows the team · via University of Cambridge
knows the team · via Howard Hughes Medical Institute
knows the team · via Syndex Bio
×4knows the team · via The University of Sheffield
×2knows the team · via University of Southampton
Syndex develops mcPCR (methyl copying PCR), a proprietary platform technology that amplifies DNA while preserving methylation patterns, addressing the challenge of low DNA levels in clinical samples. The technology targets clinical applications including oncology and early cancer detection, residual disease and treatment monitoring, drug development, and chronic disease detection.
Founders & leadership
Syndex was founded in 2022 by Geoff Smith.
GS
Geoff SmithinFounder & CEOGeoff Smith led Technology Development globally at Illumina, where he was involved in developing NGS workflows including sample preparation, sequencing technology, and instrument systems. He has experience in next-generation sequencing applications spanning oncology, infectious disease detection, and other clinical domains.
JB
Jason BetleyinChief Product OfficerHe previously held VP-level positions in research and technology development at biotech companies, holds a PhD from the University of Sheffield, and completed a postdoctoral fellowship at the University of Colorado at Boulder, with expertise in chemistry, DNA sequencing, and biochemistry.
Investors · 3
Reported raises · per SEC filings
Form D private placements$15.5M disclosed across 1 round · 2025
▶$15.5MraisedMar 2025 · 12 investors · BiotechnologyRule 506(b)
▶$15.5MraisedMar 2025 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Geoff Paul SmithExecutive Officer, Director
- Offering amount
- $15.5M
- Amount sold
- $15.5M
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlapThumbnail for SyntheX10 shared keywordsSyntheX develops the ToRFLEx platform, a first-in-class drug discovery technology that enables screening for compounds that modulate protein-protein interactions and targeted protein degradation for previously inaccessible drug targets identified by geneticists. The company builds an internal oncology pipeline and partners with external organizations to expand adoption of its platform.
Syenex6 shared keywordsSyenex provides cell delivery technologies and contract development services for therapeutic cell engineering, serving biopharmaceutical companies developing cell-based therapies. The company integrates cell engineering and delivery capabilities with regulatory support for clinical development.
Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Syntax4 shared keywordsSyntax Bio develops a discovery platform that accelerates stem cell-derived therapies by using its proprietary Cellgorithm technology to control and direct cell differentiation. The platform enables biopharma companies to speed up cell therapy development, reduce manufacturing costs, and expand their pipeline of potential treatments.
Senex Biotechnology4 shared keywordsSenex Biotechnology develops cancer and chronic disease therapies by targeting aging-related biological pathways identified through functional genomics. The company focuses on oncology indications including ovarian, breast, and prostate cancers.
SOSV Visit SOSV3 shared keywordsSOSV is a venture capital firm that provides pre-seed funding (up to $550,000) to founders in deep technology sectors including life sciences, robotics, industrial automation, energy transition, and medical technology. The firm operates accelerator programs in New York City, San Francisco, and Newark, NJ, and does not invest in enterprise software, fintech, blockchain, crypto, cybersecurity, or ecommerce.
Synlogic3 shared keywordsSynlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases. The company applies synthetic biology approaches to design programmable therapeutic candidates for patients.
Companies competing with Syndex for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Syndex do?
- Syndex develops mcPCR (methyl copying PCR), a proprietary platform technology that amplifies DNA while preserving methylation patterns, addressing the challenge of low DNA levels in clinical samples. The technology targets clinical applications including oncology and early cancer detection, residual disease and treatment monitoring, drug development, and chronic disease detection.
- Who founded Syndex?
- Syndex was founded by Geoff Smith in 2022.
- Who are Syndex's investors?
- Syndex's investors include OMX Ventures, +ND Capital, ARCH Venture Partners.
- How much funding has Syndex raised?
- Syndex has disclosed $15.5M raised across 1 round.
- Where is Syndex headquartered?
- Syndex is headquartered in Santa Monica, US.